Last reviewed · How we verify
acid mycophenolic (Myfortic)
Acid mycophenolic inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine nucleotides.
Acid mycophenolic inhibits inosine monophosphate dehydrogenase (IMPDH), an enzyme involved in the de novo synthesis of guanosine nucleotides. Used for Prevention of organ rejection in kidney transplant patients.
At a glance
| Generic name | acid mycophenolic (Myfortic) |
|---|---|
| Also known as | Bitherapy: Association of low dose corticosteroids 0.5 mg/kg/day and Myfortic ® at a dose of 1440 mg/day. |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | immunosuppressant |
| Target | inosine monophosphate dehydrogenase (IMPDH) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting IMPDH, acid mycophenolic reduces the proliferation of T and B lymphocytes, which are key components of the immune system. This action is particularly beneficial in preventing organ rejection in transplant patients. Additionally, the inhibition of IMPDH can also affect the function of other cells, such as dendritic cells and natural killer cells, which play a role in the immune response.
Approved indications
- Prevention of organ rejection in kidney transplant patients
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Headache
- Fatigue
- Infection
- Anemia
- Leukopenia
- Thrombocytopenia
Key clinical trials
- Belimumab and Rituximab Combination Therapy for the Treatment of Diffuse Cutaneous Systemic Sclerosis (PHASE2)
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- acid mycophenolic (Myfortic) CI brief — competitive landscape report
- acid mycophenolic (Myfortic) updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI